Pipeline

Product

Indication

Preclinical Phase 1 Phase 2 Phase 3 Registration
Internal clinical development

Tesomet

Prader-Willi syndrome

Hypothalamic obesity

Metabolic diseases

SAN711

Itching and neuropathic pain

Partnered clinical development

Tesofensine

Obesity

NS2359

Cocaine addiction

CAD-1883

Essential tremor

Spinocerebellar ataxia

Non disclosed

Schizophrenia

Completed

Ongoing

In planning